CD180 and marginal zone lymphoma: The addition of CD180 in the flow cytometry and immunohistochemistry panel has made it possible to better classify these lymphomas with sensitivity and specificity evaluated at least at 75% and 90%, respectively [19,20], making CD180 a helpful immunologic marker in MZL.